Skye Bioscience Inc
NASDAQ:SKYE
Balance Sheet
Balance Sheet Decomposition
Skye Bioscience Inc
Skye Bioscience Inc
Balance Sheet
Skye Bioscience Inc
| Oct-2011 | Oct-2012 | Oct-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||
| Cash & Cash Equivalents |
0
|
0
|
0
|
0
|
3
|
0
|
0
|
2
|
2
|
2
|
9
|
1
|
1
|
70
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
9
|
1
|
0
|
2
|
|
| Cash Equivalents |
0
|
0
|
0
|
0
|
3
|
0
|
0
|
2
|
2
|
0
|
0
|
0
|
1
|
68
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
8
|
10
|
0
|
|
| Total Current Assets |
0
|
0
|
0
|
0
|
3
|
0
|
1
|
2
|
2
|
3
|
10
|
9
|
12
|
71
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
0
N/A
|
0
+33%
|
0
+275%
|
0
+133%
|
4
+903%
|
0
-91%
|
1
+75%
|
2
+250%
|
2
+2%
|
3
+34%
|
10
+269%
|
9
-8%
|
12
+31%
|
73
+509%
|
|
| Liabilities | |||||||||||||||
| Accounts Payable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
1
|
1
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
2
|
2
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
4
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
2
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
16
|
1
|
0
|
0
|
6
|
6
|
2
|
|
| Total Current Liabilities |
0
|
0
|
0
|
1
|
1
|
1
|
1
|
16
|
1
|
1
|
4
|
12
|
14
|
4
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
1
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
2
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
0
N/A
|
0
N/A
|
0
N/A
|
1
+1 233%
|
3
+280%
|
2
-42%
|
1
-23%
|
18
+1 188%
|
1
-92%
|
2
+53%
|
4
+80%
|
12
+204%
|
14
+16%
|
5
-67%
|
|
| Equity | |||||||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
1
|
1
|
3
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
|
| Retained Earnings |
0
|
0
|
0
|
3
|
7
|
10
|
13
|
32
|
32
|
39
|
47
|
67
|
104
|
131
|
|
| Additional Paid In Capital |
0
|
0
|
0
|
2
|
6
|
7
|
9
|
16
|
33
|
39
|
53
|
63
|
102
|
199
|
|
| Total Equity |
0
N/A
|
0
+33%
|
0
+100%
|
0
N/A
|
0
N/A
|
1
N/A
|
1
+45%
|
16
-1 845%
|
1
N/A
|
0
-18%
|
6
+1 202%
|
3
N/A
|
2
+29%
|
68
N/A
|
|
| Total Liabilities & Equity |
0
N/A
|
0
+33%
|
0
+275%
|
0
+133%
|
4
+903%
|
0
-91%
|
1
+75%
|
2
+250%
|
2
+2%
|
3
+34%
|
10
+269%
|
9
-8%
|
12
+31%
|
73
+509%
|
|
| Shares Outstanding | |||||||||||||||
| Common Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
2
|
4
|
12
|
31
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|